Himadri Speciality Chemical Ltd announces Q1 FY27 financials and business updates
Himadri Speciality Chemical · Chemicals & Petrochemicals
Key highlights
- Q1 FY27 standalone net profit after tax was ₹223.42 crore on revenue from operations of ₹1,274.26 crore; consolidated net profit after tax was ₹228.43 crore on revenue from operations of ₹1,431.88 crore.
- Board approved ₹128 crore capex to expand Anthraquinone and Carbazole manufacturing capacity from 2,600 MTPA to 5,300 MTPA.
- Board approved ₹70 crore investment for new Carbon Nano Tubes (CNT) production line with capacity of 200 MTPA, to be funded through internal accruals.
Why it's rated notable: the year-on-year change is 27% (20% to 50%)
Original filing
Board Meeting Outcome for Outcome Of Board Meeting Held On 15 July 2026
Read the filing on BSE (PDF) →Companies guiding to strong growth
Ranked by management's own guidance on revenue and margins — not by us.
Aerospace & Defense
Sign up free to see all 6 →
See full rankingsRank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
More from Himadri Speciality Chemical
- Capex / expansionNotableHimadri Speciality Chemical Ltd reports record Q1FY27 revenue and profit
- Capex / expansionNotableHimadri Speciality Chemical Ltd starts first anode material production facility
- Dividend / buyback / bonusNotableHimadri Speciality Chemical Ltd announces FY 2026 audited results and new subsidiary plans
- Dividend / buyback / bonusNotableHimadri Speciality Chemical Ltd announces FY 2025-26 audited results and dividend proposal
- Capex / expansionNotableHimadri Speciality Chemical Ltd Reports Record FY26 Results and New Facility Launches
Other capex / expansion filings this fortnight
- Maharaja & Speedex India Limited raises manufacturing capacity to 72 lakh units/year
- Elin Electronics Q2 FY27 earnings report with 10% revenue growth and margin update
- HOAC Foods India Limited H1 FY27 Earnings Call Transcript dated November 5, 2026
- Gujarat State Fertilizers & Chemicals Limited Q2 FY27 Earnings Call Highlights
- Supriya Lifescience H1 revenue up 14.8% to ₹396.04 crore; Q2 profit falls
- V-MARC India Ltd announces Q2 & H1 FY27 unaudited financial results and review report
Potential multibaggers · Q2 FY27
Potential multibaggers in Chemicals & Petrochemicals
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Summary written by Arthneeti from the company's filing with the stock exchange; check the original filing for full details. Arthneeti is a research and analytics platform, not a SEBI-registered investment adviser, and nothing here is a recommendation to buy or sell.